stockrow
Friday 6 November 2026
Export DXR’s income statement to Excel — free account
Daxor Corporation
DXR Healthcare Medical Instruments & Supplies
Daxor Corporation’s revenue for fiscal 2022 (year ended December 2022) was −$353,400.00.
8.63
0.28
−3.14%
Follow DXR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM Jun ’23 | Trend | 10 yrs | 2023e | 2024e | 2025e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 1 | (1) | (1) | 2 | (3) | (3) | 0 | (3) | n/m | — | — | 7 | n/m | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | 1 | (1) | (1) | 0 | (2) | 5 | 5 | 8 | +23.4% | ||||||
| EBT margin, % | — | — | — | 219.67 | 83.18 | 93.16 | (28.47) | 61.67 | (181.56) | (1,465.22) | (251.91) | (1,684.9) pt | ||||||
| Net income | — | — | — | 1 | (1) | (1) | 0 | (2) | 5 | 5 | 8 | +23.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.17 | (0.39) | (0.35) | 0.46 | (0.71) | (0.65) | (0.09) | (0.75) | n/m | |||||
| Earnings | — | — | — | 0.38 | (0.33) | (0.24) | (0.13) | (0.43) | 1.18 | 1.27 | 2.15 | +22.3% | ||||||
| Cash flow | — | — | — | 0.35 | (0.60) | (0.35) | (0.55) | (0.72) | (0.70) | (0.85) | (1.68) | n/m | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | 0.35 | (0.60) | (0.35) | (0.55) | (0.72) | (0.70) | (0.85) | (1.68) | n/m | ||||||
| Book value | — | — | — | 4.01 | 3.65 | 3.49 | 3.41 | 3.98 | 5.24 | 7.09 | 6.80 | +10.0% | ||||||
| Shares, m | — | — | — | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | +1.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.68 | 3.67 | 4.01 | 2.8 | |||||
| P/S | — | — | — | 24.80 | 12.90 | 0.00 | 82.18 | 0.00 | 0.00 | 0.00 | 0.00 | 17.1 | ||||||
| P/B | — | — | — | 0.99 | 0.52 | 2.35 | 2.76 | 3.22 | 2.15 | 1.27 | 1.27 | 1.9 | ||||||
| EV/Sales | — | — | — | 7.08 | (4.82) | (58.90) | 85.27 | (49.34) | (9.35) | (13.47) | (12.50) | (6.2) | ||||||
| EV/FCF | — | — | — | (1.54) | 1.05 | (12.05) | (10.77) | (10.79) | (8.97) | (6.35) | (5.57) | (7.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 1 | (2) | (1) | (2) | (3) | (3) | (3) | (8) | n/m | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Free cash flow | — | — | — | 1 | (2) | (1) | (2) | (3) | (3) | (3) | (8) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | 32 | — | |||||
| Net debt | — | — | — | 1 | 3 | 4 | 1 | 0 | 2 | 1 | 1 | +12.1% | ||||||
| Shareholders’ equity | — | — | — | 15 | 14 | 13 | 13 | 16 | 21 | 29 | 30 | +11.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 7.01 | (6.21) | (4.80) | (3.11) | (11.09) | 22.86 | 18.75 | 35.90 | +11.7 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 9.78 | (8.52) | (6.61) | (3.84) | (11.99) | 25.79 | 20.66 | 37.62 | +10.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2022 · latest quarter Jun 2023
Daxor Corporation vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KRMD KORU Medical Systems, Inc. | $139.9M | — (loss-making) | — (loss-making) | +18.15% (above 0%: growing) | n/m | +26.17% (above 0%: growing) | 65.14% | 5.21% | Compare |
| STXS Stereotaxis Inc. | $105.2M | — (loss-making) | — (loss-making) | −12.82% (below 0%: shrinking) | n/m | +0.45% (above 0%: growing) | 58.49% | (59.56%) | Compare |
| ZTEKF Zentek Ltd. | $62.3M | — (loss-making) | — | −95.36% (below 0%: shrinking) | n/m | −254.61% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| POCI Precision Optics Corp. | $54.3M | — (loss-making) | — (loss-making) | +41.95% (above 0%: growing) | n/m | −45.64% (below 0%: shrinking) | 25.34% | (1.21%) | Compare |
| DXR Daxor Corporation | $50.4M | 4.0× | 7.6× | −27.62% (below 0%: shrinking) | n/m | −88.56% (below 0%: shrinking) | 0.00% | 0.00% | |
| HBIO Harvard Bioscience, Inc. | $38.5M | — (loss-making) | — (loss-making) | +11.13% (above 0%: growing) | n/m | −123.43% (below 0%: shrinking) | 55.57% | (4.30%) | Compare |
| NEPH Nephros Inc. | $33.6M | 18.0× | 20.2× | +18.01% (above 0%: growing) | +66.67% (above 0%: growing) | −251.52% (below 0%: shrinking) | 58.45% | 8.91% | Compare |
| DAVI Davion Healthcare PLC | $32.8M | — | — | — | — | — | — | — | Compare |
| MLSS Milestone Scientific, Inc. | $27.1M | — (loss-making) | — (loss-making) | +22.27% (above 0%: growing) | n/m | +66.68% (above 0%: growing) | 67.24% | (37.37%) | Compare |
| Median of peers | $46.4M | — | — | +18.01% | — | −45.64% | 58.45% | (1.21%) |
Pay and ownership Proxy statement filed 3 June 2026
Ownership
Directors and executive officers, together
51.50%
Estate of Joseph Feldschuh (c)
43.70%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement